Publications by authors named "Christopher Danes"

Claim this Profile
O
Oncologists' preferences for first-line treatment of ALK-positive metastatic NSCLC in the United States: a discrete choice experiment.
Kathryn F Mileham, Laura Panattoni, Grace Gahlon, Pedro Labisa, Nicole Bariahtaris, Christopher Danes

Future Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editor's Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
Lingegowda S Mangala, Vesna Zuzel, Rosemarie Schmandt, Erik S Leshane, Jyotsna B Halder, Christopher G Danes

Clin Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis.
Cody Paiva, J Claire Godbersen, Taylor Rowland, Olga V Danilova, Christopher Danes

Oncotarget· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erythropoietin Stimulates Tumor Growth via EphB4.
Sunila Pradeep, Jie Huang, Edna M Mora, Alpa M Nick, Min Soon Cho, Christopher Danes

Cancer Cell· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.
William M Merritt, Christopher G Danes, Mian M K Shahzad, Yvonne G Lin, Aparna A Kamat

Cancer Biol Ther· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual targeting of EphA2 and FAK in ovarian carcinoma.
Mian M K Shahzad, Chunhua Lu, Jeong-Won Lee, Rebecca L Stone, Rahul Mitra, Christopher G Danes

Cancer Biol Ther· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
Lingegowda S Mangala, Vesna Zuzel, Rosemarie Schmandt, Erik S Leshane, Jyotsna B Halder, Christopher G Danes

Clin Cancer Res· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival.
Christopher L Neal, Jun Yao, Wentao Yang, Xiaoyan Zhou, Nina T Nguyen, Christopher G Danes

Cancer Res· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional significance of VEGFR-2 on ovarian cancer cells.
Whitney A Spannuth, Alpa M Nick, Nicholas B Jennings, Guillermo N Armaiz-Pena, Lingegowda S Mangala, Christopher G Danes

Int J Cancer· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling.
Christopher G Danes, Shannon L Wyszomierski, Jing Lu, Christopher L Neal, Wentao Yang

Cancer Res· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis